Biophytis completes €5.3 million private placement to fund Phase 2 obesity trial

• Biophytis priced a €5.3 million private placement of new shares with attached warrants, including €4.75 million cash and €0.55 million debt rollover.
• Issued 101,923,092 new shares at €0.05 each, a 24.1% discount to the 10-day volume-weighted average price.
• Placement also included 127,403,865 warrants exercisable at €0.06 per share within 60 months.
• Proceeds earmarked to fund the Phase 2 OBA obesity trial, extending cash runway to at least Q1 2028.
• Shares outstanding rise to 350,132,497 post-offering, with €8.9 million in cash and cash equivalents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-107184), on September 14, 2026, and is solely responsible for the information contained therein.